DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 124 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 0.06 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $475,310 | -11.7% | 29,000 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $538,000 | +41.2% | 29,000 | 0.0% | 0.01% | +40.0% |
| Q2 2022 | $381,000 | -81.9% | 29,000 | -86.5% | 0.01% | -78.3% |
| Q4 2021 | $2,101,000 | -18.2% | 215,000 | +184.4% | 0.02% | -20.7% |
| Q3 2021 | $2,569,000 | -14.9% | 75,603 | -8.4% | 0.03% | -27.5% |
| Q2 2021 | $3,020,000 | +10.1% | 82,500 | +35.0% | 0.04% | -32.2% |
| Q1 2021 | $2,742,000 | -31.4% | 61,100 | -12.7% | 0.06% | -35.9% |
| Q4 2020 | $3,996,000 | -13.5% | 70,000 | -22.2% | 0.09% | -14.8% |
| Q3 2020 | $4,619,000 | -40.5% | 90,000 | -30.8% | 0.11% | -58.1% |
| Q2 2020 | $7,766,000 | +45.2% | 130,000 | 0.0% | 0.26% | -14.6% |
| Q1 2020 | $5,350,000 | -42.7% | 130,000 | -13.3% | 0.30% | -3.5% |
| Q4 2019 | $9,332,000 | +587.2% | 149,900 | +274.8% | 0.31% | +347.1% |
| Q3 2019 | $1,358,000 | -85.9% | 40,000 | -90.7% | 0.07% | -85.6% |
| Q2 2019 | $9,649,000 | – | 427,900 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $69,030,000 | 15.95% |
| SV Health Investors, LLC | 449,951 | $25,679,000 | 12.37% |
| Sunesis Advisors, LLC | 96,299 | $5,496,000 | 4.45% |
| Redmile Group, LLC | 4,437,968 | $253,275,000 | 3.07% |
| Consonance Capital Management LP | 484,671 | $27,660,000 | 2.58% |
| SECTORAL ASSET MANAGEMENT INC | 488,842 | $27,898,000 | 1.97% |
| Opaleye Management Inc. | 222,000 | $12,670,000 | 1.66% |
| Eversept Partners, LP | 246,240 | $14,052,917 | 1.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 38,620 | $2,204,000 | 1.28% |
| Avoro Capital Advisors LLC | 1,300,000 | $74,191,000 | 1.28% |